PURPOSE OF REVIEW: The aim is to describe and quantify the association between genitourinary tract infections and preterm birth. RECENT FINDINGS: Recent studies confirm the importance of identifying and treating both asymptomatic and symptomatic bacteriuria in pregnancy, which is reflected in current antenatal screening guidelines. These guidelines do not recommend routine screening for other asymptomatic lower genital infections (bacterial vaginosis, trichomonas and gonorrhoea) reflecting inconsistent study results, which may reflect differences in study design, size, diagnostics and the timing of screening in pregnancy. Screening for group B Streptococcus (GBS) late in pregnancy is recognized to reduce neonatal disease, but there is a striking lack of robust studies, specifically randomized controlled trials (RCTs), considering the effect of GBS screening earlier in pregnancy on adverse pregnancy outcomes. SUMMARY: The potential for screening and treatment of genitourinary tract infections in pregnancy to reduce preterm birth rates has been demonstrated in some RCTs. Current guidelines do not reflect these data because of inconsistencies across the body of evidence. There is a need for robust RCTs to confirm or refute earlier data, to inform the optimal timing for screening in pregnancy and to better quantify the contribution of individual infections to the burden of preterm birth.
PURPOSE OF REVIEW: The aim is to describe and quantify the association between genitourinary tract infections and preterm birth. RECENT FINDINGS: Recent studies confirm the importance of identifying and treating both asymptomatic and symptomatic bacteriuria in pregnancy, which is reflected in current antenatal screening guidelines. These guidelines do not recommend routine screening for other asymptomatic lower genital infections (bacterial vaginosis, trichomonas and gonorrhoea) reflecting inconsistent study results, which may reflect differences in study design, size, diagnostics and the timing of screening in pregnancy. Screening for group B Streptococcus (GBS) late in pregnancy is recognized to reduce neonatal disease, but there is a striking lack of robust studies, specifically randomized controlled trials (RCTs), considering the effect of GBS screening earlier in pregnancy on adverse pregnancy outcomes. SUMMARY: The potential for screening and treatment of genitourinary tract infections in pregnancy to reduce preterm birth rates has been demonstrated in some RCTs. Current guidelines do not reflect these data because of inconsistencies across the body of evidence. There is a need for robust RCTs to confirm or refute earlier data, to inform the optimal timing for screening in pregnancy and to better quantify the contribution of individual infections to the burden of preterm birth.
Authors: Raina N Fichorova; Noah Beatty; Rita R S Sassi; Hidemi S Yamamoto; Elizabeth N Allred; Alan Leviton Journal: Am J Reprod Immunol Date: 2014-08-28 Impact factor: 3.886
Authors: Hae-Ryung Park; Sean M Harris; Erica Boldenow; Richard C McEachin; Maureen Sartor; Mark Chames; Rita Loch-Caruso Journal: Biol Reprod Date: 2018-03-01 Impact factor: 4.285
Authors: Alan Leviton; Elizabeth N Allred; Karl C K Kuban; T Michael O'Shea; Nigel Paneth; Andrew B Onderdonk; Raina N Fichorova; Olaf Dammann Journal: Am J Epidemiol Date: 2015-12-13 Impact factor: 4.897
Authors: E R Begnel; A L Drake; J Kinuthia; D Matemo; M-L Huang; K H Ásbjörnsdóttir; V Chohan; K Beima-Sofie; G John-Stewart; D Lehman; J Slyker Journal: Clin Exp Immunol Date: 2020-12-20 Impact factor: 5.732
Authors: John P Newnham; Matthew W Kemp; Scott W White; Catherine A Arrese; Roger J Hart; Jeffrey A Keelan Journal: Front Public Health Date: 2017-04-04
Authors: Fiorella Bianchi-Jassir; Anna C Seale; Maya Kohli-Lynch; Joy E Lawn; Carol J Baker; Linda Bartlett; Clare Cutland; Michael G Gravett; Paul T Heath; Margaret Ip; Kirsty Le Doare; Shabir A Madhi; Samir K Saha; Stephanie Schrag; Ajoke Sobanjo-Ter Meulen; Johan Vekemans; Craig E Rubens Journal: Clin Infect Dis Date: 2017-11-06 Impact factor: 9.079